Human adenoviruses associated with respiratory illness in neonates, infants, and children in the Sousse area of Tunisia

Ines Brini1,2,3,4 | Aida Guerrero4,5 | Issaad-Kawther Ezzine6 | Dorothea Orth-Höller4,7 | Benjamin Hetzer4,8 | Reinhard Würzner4,7 | Olfa Hazgui2,3 | Imene Handous2,3 | Sonia Nouri-Merchaou3,9 | Jihene Bouguila3,10 | Nabiha Mahdhaoui3,9 | Lamia Boughamoura3,10 | Zahra Malekshahi4,5 | Dorothee von-Laer4,5 | Naila Hannachi2,3 | Jalel Boukadida2,3 | Heribert Stoiber4,5

1Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia
2Laboratoire de Microbiologie, Unité de Recherche Caractérisation Génomique des Agents Infectieux UR12SP34, Hôpital Universitaire Farhat Hached Sousse, Université de Sousse, Sousse, Tunisie
3Faculté de Médecine de Sousse, Université de Sousse, Sousse, Tunisie
4Medical University of Innsbruck, Innsbruck, Austria
5Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria
6Laboratoire de Génétique, Biodiversité et Valorisation des Bio-ressources, Institut Supérieur de Biotechnologie de Monastir, Université de Monastir, Monastir, Tunisie
7Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria
8Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria
9Service de Néonatologie, Hôpital Universitaire Farhat Hached Sousse, Université de Sousse, Sousse, Tunisie
10Service de Pédiatrie, Hôpital Universitaire Farhat Hached Sousse, Université de Sousse, Sousse, Tunisie

Correspondence
Ines Brini, Faculté de Pharmacie de Monastir, Université de Monastir, Rue Ibn Sina, 5000, Monastir, Tunisia.
Email: ines.brini@hotmail.com
Heribert Stoiber, Institute of Virology, Medical University of Innsbruck, Peter-Maystr 4b A-6020, Innsbruck, Austria.
Email: Heribert.stoiber@i-med.ac.at

Funding Information
Austrian Science Fund, Grant/Award Number: W1253-B24, Ministry of Higher Education and Scientific Research in Tunisia (MHESR)

Abstract
Background: The human Adenovirus (HAdV) is a common agent of acute respiratory infections (ARIs). Its clinical impact in immunocompetent children and in the context of coinfections remains unclear in Tunisia.

Material and methods: HAdV-ARIs were studied in hospitalized patients from birth to the age of 5 years from 2013 to 2014. Clinical and demographic characteristics, coinfections, and molecular characterization of HAdV were established.

Results: HAdV-positivity was detected in 114/583 specimens (19.6%) including 6.1% single infections and 93.9% coinfections. Adenoviral coinfections mostly comprised human Rhinovirus (50.9%), Streptococcus pneumoniae (34.2%), human Respiratory Syncytial virus A/B (29.8%), and human Coronaviruses (21.9%). HAdV infection was predominant in the pediatric population (25.0% vs 10.0% in neonates, \( P < .001 \)) and peaked in February 2014 (21.1%). HAdV severity of pediatric cases is characterized by low saturation of oxygen (<94%, 33.8%, \( P = .05 \)) and long duration of oxygen support (≥5 days, 32.7%, \( P = .02 \)). Severe HAdV infections were described with S. pneumoniae coinfection, which

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Journal of Medical Virology Published by Wiley Periodicals LLC
seemed to increase the risk of death. HAdV genotyping identified HAdV-C as the most common species. Severe ARIs were observed in all HAdV-identified types. Phylogenetic analysis revealed that sequences were variable suggesting the circulation of different HAdV strains sharing more similarities to strains circulating in Europe or Asia than those from Africa. 

**Conclusion:** This first molecular study of HAdV in Tunisia demonstrated that it has an important role in severe ARIs with HAdV-C being the most common species. S. pneumoniae co-detection seems to increase the severity of HAdV-ARIs.

**KEYWORDS**
acute respiratory infections, coinfections, genotyping, human Adenovirus, severity, Tunisia

## INTRODUCTION

Acute respiratory infections (ARIs) are a significant cause of childhood mortality and morbidity worldwide. Various respiratory pathogens are identified as causative agents for respiratory symptoms including the human Adenovirus (HAdV). This pathogen is classified among the Adenoviridae family and belongs to the genus Mastadenovirus. It is a ubiquitous nonenveloped virus of medium-sized double-stranded-DNA ranging from 34 kb to more than 37 kb, which encodes around 40 genes.

HAdV has been divided into seven species (A-G) based on a biological criteria and DNA homology. Each species comprises multiple genotypes. According to the Human Adenovirus Working Group, the collaboration between adenoviral researchers and the National Center for Biotechnology Information (NIH)/GenBank, up to 90 genotypes of HAdV have been described. These genotypes were designated with a number according to the chronological order of identification. The distribution of HAdV genotypes is variable, depending on geographical, environmental, and meteorological characteristics. Some strains may have a higher epidemic potential. Several species were found to be associated with different clinical profiles. Those most common genotypes implicated in ARIs belong to HAdV-C (types 1, 2, 5, and 6), HAdV-B (types 3 and 7), and HAdV-E (a single type 4) species. Severe and fatal adenoviral diseases were found to be caused by HAdV-B types 14, 21, and 55. However, HAdV circulating genotypes in the context of ARIs have not yet been described in Tunisia.

HAdV was found to be one of the causative agents of tonsillopharyngitis, conjunctivitis, pneumonia, gastroenteritis, hepatitis, and hemorrhagic cystitis. In terms of ARIs, this virus causes between 5% and 15% of the overall respiratory illnesses in children aged below 4 years. Severe or life-threatening respiratory diseases in immunocompromised cases were frequently reported in the context of adenoviral infection. In addition, HAdV severe infection was also described in immunocompetent patients. Nonetheless, its detection in respiratory specimens does not necessarily identify HAdV as the causative agent of ARIs but may be related to reactivation or latency, especially, when highly sensitive molecular detection tests are used. Conversely, some authors have found that there is enhanced severity and worse outcomes in children with mixed respiratory viral infection as compared with those with single infections. Thus, the role of adenoviral coinfections in ARIs remains controversial and warrants additional research.

The detection of HAdV and the identification of its pathogenicity in ARIs were poorly reported in North Africa. Although in Tunisia HAdV-ARIs were previously described, the molecular characterization of this pathogen was only performed in non-ARIs. This study aimed to assess the severity of HAdV and detected coinfections in neonates, infants, and children hospitalized for ARIs in a Central-East region of Tunisia. The molecular characterization of HAdV was determined. This study highlights the importance of HAdV detection and its coinfections in ARIs and provides the first starting point on the circulation of different genotypes in Tunisia. Such evidence will promote the initiation of preventive measurements against the circulation of HAdV and the most prevalent coinfected pathogens in the community.

## MATERIALS AND METHODS

### 2.1 Ethics and study population

This study did not involve any human experimentation. The study protocol was approved with formal authorization from the Scientific and Ethical Committee of the "Hôpital Universitaire Farhat Hached (CHU-FH) Sousse, Tunisie," approval number-Institutional Review Board-00008931, and provided by the Office for Human Research Protections. This cross-sectional study covering the period of 1 October 2013 to 31 December 2014 included patients from birth to 5 years of age who were hospitalized for ARIs in the neonatology and pediatric wards of the "CHU-FH Sousse, Tunisie." The diagnosis of ARIs was carried out according to the recommendations of the Tunisian Society of Pediatrics in 2013. Patients’ data including demographic characteristics, medical history, clinical manifestations, and bacteriology tests, were extracted from medical charts.

### 2.2 Detection of HAdV and other common respiratory pathogens

Nasopharyngeal aspirates were obtained within 24 hours after admission and transported to the Laboratory of Microbiology at the same hospital. Samples were diluted in phosphate-buffered saline and centrifuged for 10 minutes/3584 × g/+4°C. Using appropriate transport conditions,
supernatants were transferred to the Innsbruck Medical University, Austria, where they were directed for the pathogenic genomic detection, bacterial identification, and typing and sequencing reactions.

### 2.2.1 | Multiplex detection of respiratory pathogens by real-time reverse-transcription polymerase chain reaction

A magnetic-particle technology for automated isolation of total nucleic acids was executed using the QIAsymphony Sp automate (QIAGEN; Cat No. /ID: 9001297; Hilden; Germany) and the QIAsymphony DSP virus/Pathogen Mini Kit (QIAGEN; Vienna; Austria). A final volume of 150 µL of extracted nucleic acids was obtained and used for the genomic detection of respiratory pathogens by a multiplex quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) with the Fast Track Diagnostics (FTD) Respiratory pathogens 21 Kit (FTD-2-64; Luxemburg S.à.r.l.; 29; rue Henri Koch; L-4354 Esch-sur-Alzette). This is a qualitative in vitro diagnostics system generating five-tube multiplex for the detection of: Influenza A virus (InfV-A); Influenza B virus (InfV-B); Influenza A(H1N1) virus swine-lineage (InfV-A(H1N1)sw); Human Rhinovirus (HRV) in the first mixture, Human Coronavirus NL63 (HCoV-NL63); Human Coronavirus 229E (HCoV-229E); Human Coronavirus OC43 (HCoV-OC43); Human Coronavirus HKU1 (HCoV-HKU1) in the second mixture, Human Parainfluenza virus 2 (HPIV-2); Human Parainfluenza virus 3 (HPIV-3); Human Parainfluenza virus 4 (HPIV-4); internal control in the third mixture, Human Parainfluenza virus 1 (HPIV-1); Human Metapneumovirus A/B (HMPV A/B); Human Bocavirus (HBoV); Mycoplasma pneumoniae in the fourth mixture, and Human Respiratory Syncytial virus A/B (HRSV A/B); HAdV; Enterovirus genus (EV); Human Parechovirus genus (HPeV) in the fifth mixture, using specific primers and probes. The presence of pathogen sequences is detected by an increase in fluorescence (relevant dual-labeled probe) which is interpreted by the cycle threshold (Ct) value.

### 2.2.2 | Streptococcus pneumoniae genomic detection

*S. pneumoniae* genome detection was performed by the 16S ribosomal DNA qPCR and using the Light Cycler Fast Start DNA Mas (#03003248001) kit as per manufacturer’s instructions. The primers and probe were designed by Corless and collaborators.23 For all reactions of HAdV detection and other respiratory agents, PCR mixtures and programs were previously provided.15,16

### 2.3 | HAdV typing, sequencing, and phylogenetic analysis of the partial hexon gene

#### 2.3.1 | Genotyping of adenoviruses

Table 1 shows the primer sets used for HAdV molecular identification. Typing reactions were assessed starting from a first PCR (1st PCR) using universal primers designated according to the hypervariable region (HVR) of the hexon gene for all HAdV prototypes (primers set 1). A nested PCR (1st nested PCR) for the typing of HAdV-C2; -B3; -E4; -B7; and -B11 was carried out (primers sets 2-6). For HAdV-B14 identification, a second PCR (2nd PCR) was performed using primers sets 8 and 9, respectively. A third PCR (3rd PCR) was done for the detection of HAdV-B55 (primers set 10).

#### 2.3.2 | Sequencing of HAdV positive specimens

PCR for sequencing a partial region of the hexon gene specific to all HAdVs prototypes and containing the HVR-7, was performed according to Sarantis et al.24 In addition to Tunisian samples, two specimens from Innsbruck were used as control for the optimization of HAdV sequencing reaction (see Table, Supplemental Digital Content 1 that summarizes the HAdV reference sequences targeting a partial hexon gene and control specimens used to generate the phylogenetic tree). Each specimen was analyzed based on Sanger sequencing technology using AD1 and AD2 primers,24 accordingly.

#### 2.3.3 | Analysis of nucleotide sequences and construction of the phylogenetic tree

Forward and reverse sequences were assembled, examined for ambiguities, and aligned using default settings of “Clustal W” implemented in BioEdit v.7.2.5.25 Sequences were trimmed to generate a standard 638 nucleotide-long fragment then compared with HAdV Hexon gene sequences available on Genbank to estimate their identities. The comparison was performed using the BLASTn program from the US National Center for Biotechnology Information. Sequences of relevant prototypes relative to circulating strains worldwide and which have significant homology percentages with our sequences (≥98%) were downloaded and used as reference sequences (Supplemental Digital Content 1).

For Bayesian Inference, Bayes v.3.2.226 was used under a mixed evolution model. Four independent runs were conducted for 10^6 generations, sampling every 1000. The first 25% trees were discarded as default burn-in and a majority rule consensus tree was calculated from the remaining trees. The obtained topology and the posterior probabilities of each node were displayed on FigTree v.1.4.0.27

### 2.4 | Data analysis and statistics

The Ct-value corresponds to the number of cycles required for the fluorescent signal, determined by the accumulation of a fluorescent signal during qPCR/qRT-PCR to cross the threshold and indicating viral loads in specimens. Data were analyzed for statistical significance with the Statistical Package for the Social Sciences (IBM SPSS Statistics, v.24.0) using Pearson’s χ^2 test or Fisher’s exact test (where cell counts < 5 were encountered). The odds ratio (OR) and 95% confidence interval
| Set/Ref | Primer | HAdV | Target | Region | PCR product (bp) | Sequence (5′-3′) |
|---------|--------|------|--------|--------|-----------------|-----------------|
| 1 (37)  | HVR-F  | Conserved | 18473-18495 | HVR of hexon gene (1st PCR) | 1684 | CAGGATGCTTGGAGTACCTGAG |
|         | HVR-R  |        | 20157-20132 |                    |                 | TTTCTGAAGTTCCTAAGTGTGA |
| 2 (38,39)| AdV2-F | HAdV-C type 2 | 18858-18883 | Partial hexon gene (1st nested PCR) | 300 | GCCGCAGTGGTCTTACATGCACATC |
|         | AdV2-R |        | 19158-19136 |                    |                 | CAGCACGCGCGAGGTCAAAGT |
| 3 (37)  | Ad3-F  | HAdV-B type 3 | 18933-18961 |                 | 313 | AAGACATTACACTGAAGGAAGAAG |
|         | Ad3-R  |        | 19246-19224 |                    |                 | CGCTAAAGTCTCTTCAACAGCAT |
| 4 (37)  | Ad4-F  | HAdV-E type 4 | 18665-18686 |                 | 323 | AGAAGGACATACCTTGGG |
|         | Ad4-R  |        | 18988-18967 |                    |                 | ATAGTTAGGAGTGGGCGCCG |
| 5 (37,40)| Ad7-F  | HAdV-B type 7 | 18890-18911 |                 | 300 | GGGAAGACATTACTGGAAGACA |
|         | Ad7-R  |        | 19190-19171 |                    |                 | AAAAAAGGTACAGAGCTTCT |
| 6' (41) | AdV11-F| HAdV-B type 11 | 19171-19187 |                | 436 | CAAGTCGAGAAGCTAAT |
|         | AdV11-R|        | 19607-19591 |                    |                 | ACCCTGTCGAGCTTCT |
| 7 (42–48,40) | AdnU-S-F | Conserved | 20743-20762 | Partial hexon gene | 955 | TTTCCCCATGGCNCACAACAC |
|         | AdnU-A-R |        | 21698-21679 |                    |                 | GCCCTCCGATGAGCCGCGGT |
| 8       | HVR-F   |        | 18473-18495 | Hexon gene (2nd PCR) | 3225 | CAGGATGCTCTGGAGTACCTGAG |
|         | AdnU-A-R |        | 21698-21679 |                    |                 | GCCCTCCGATGAGCCGCGGT |
| 9² (48,49) | AdV14-5F | HAdV-B type 14 | 19670-19689 | Partial hexon gene (2nd nested PCR) | 327 | CGCTCAATGCTCACTTTCA |
|         | AdV14-6R |        | 19997-19978 |                    |                 | CCAGGAGAACCTCTGAGC |
| 10² (51) | AdV55-2F | HAdV-B type 55 | 19672-19691 | Hexon gene (3rd PCR) | 1541 | ATACCACCGTCCGCAAAGATA |
|         | AdV55-2R |        | 21213-21194 |                    |                 | CGCCTATCGTAGGTTCCCAA |

Abbreviations: HAdV, human Adenovirus; HVR, hypervariable region; PCR, polymerase chain reaction.

²The nucleotide positions were designated according to the prototype strain of AdV-11 Slobitski strain (GenBank accession no. AF532578).
⁻²Primers were designated according to the prototype strain of HAdV-14 de Wit (GenBank accession no. AY803294).
⁻²The nucleotide positions indicated are those of the HAdV-55 strain (GenBank accession no. FJ643676).
summarizes patients’ medical data. Some identified specimens. Among the HAdV cases were fatal, comprising predominately infants and children. The need for oxygen support (87.4% in neonates and 31.4% in the pediatric population) and severity factors such as long duration of hospitalization of more than 7 days (75.8% in neonates and 45.2% in the pediatric population) and the need for oxygen support (87.4% in neonates and 31.4% in the pediatric population), were identified. During hospitalization, 6% of cases were fatal, comprising predominately infants and children.

### 3 | RESULTS

#### 3.1 | Demographic data of patients admitted for ARIs between 2013 and 2014

A total of 583 subjects from the neonatology ward (0-45 days, 36.2%) and the pediatric ward (45 days-5 years, 63.8%), of which 59.8% were infants (45 days-2 years) and 40% were children aged 2 to 5 years, hospitalized for ARIs (male predominance, sex-ratio = 1.7) were enrolled. The majority of hospitalizations for ARIs occurred in winter months (46.8% between January and March 2014). All patients had lower ARIs (LARIs) and 18.4% of cases suffered, in addition, from upper ARIs (UARIs). Table 2 summarizes patients’ medical data. Some severity factors such as long duration of hospitalization of more than 7 days (75.8% in neonates and 45.2% in the pediatric population) and the need for oxygen support (87.4% in neonates and 31.4% in the pediatric population), were identified. During hospitalization, 6% of cases were fatal, comprising predominately infants and children.

#### 3.2 | Detection of HAdV and association with clinical and severity parameters

Respiratory pathogens were found in 526/583 of specimens (90.2%), from which 28.5% were caused by a single pathogen and 71.5% by at least two pathogens. HAdV was found in 114 patients (19.6%) and was the fourth most prevalent respiratory pathogen detected after HRV (52.1%), HRSV A/B (33.3%), and S. pneumoniae (31.0%). Most cases positive for HAdV were diagnosed in February 2014 (see Figure, Supplemental Digital Content 2 describing the seasonal distribution of HAdV infections in neonates, infants, and children hospitalized for ARIs in the Sousse area between October 2013 and December 2014 [n = 583]).

HAdV infection was more frequently observed in the pediatric than neonatal population (P < .001, OR = 3). Within neonates, adenoviral infections dominated in those aged more than 10 days (12.3% of the total HAdV positive samples, P = .04). Regarding the pediatric population, HAdV infection was fluctuating between age groups (P = .01); it was increasing in the groups 13 to 60 months (36.2%) and 4 to 6 months (32.8%) while decreasing in groups 7 to 12 months (25.0%) and 45 days to 3 months (17.6%). In 33.8% of pediatric cases with HAdV infection, a low saturation of oxygen (<94%) was recorded with no statistical association. However, a statistically significant association was found between HAdV infection and long duration of oxygen support (>5 days), (32.7%, P = .02). Although hospitalized due to ARIs, HAdV infected neonates had, in addition, digestive symptoms (P = .02), and HAdV infection in pediatric patients was found to be statistically associated with gastroenteritis (P < .01) (Table 2).

#### 3.3 | Predictive adenoviral loads and impact on clinical and severity parameters

The association of clinical data and severity of ARIs with adenoviral loads (mean and median HAdV-Ct-values) showed no statistical significance, except for anemia, which increased significantly with higher adenoviral loads (see Table, Supplemental Digital Content 3 illustrating the comparison between HAdV-Ct values from positive multiplex qRT-PCR based on Ct mean = 33.4 and median = 34.6 and establishes the statistical associations between HAdV-Ct values, clinical data, and severity of ARIs).

#### 3.4 | HAdV coinfections and association with severity of ARI

Among 114 HAdV infections, seven single infections were found (6.1%). In 107 cases, coinfection with at least one other pathogen was detected (93.9%), among which HRV (50.9%), S. pneumoniae (34.2%), HRSV A/B (34.2%), and the HCoV group (including HCoV-229E, HCoV-OC43, HCoV-HKU1, and HCoV-NL63, 21.9%) dominated. Coinfections with HMPV A/B (15.8%), EV (14.0%), HPeV (11.4%), and HBoV (10.5%) were less frequent. Coinfections with other viruses were rarely detected.

The statistical associations between HAdV coinfections and severity of infection were evaluated for HRV, HRSV A/B, S. pneumoniae, and HCoV group and are given in Table 3. HAdV-S. pneumoniae was the only combination found to be associated with death (five fatal cases with HAdV-S. pneumoniae positive coinfection vs two fatal cases positive for HAdV (one monoinfection and one case together with another virus, but negative for S.pneumoniae). Due to the small sample size, no statistical calculations were performed.

#### 3.5 | Type identification of HAdVs and phylogenetic analysis

Table 4 summarizes the identified specimens. Among the HAdV positive samples, 12 were successfully typed and sequenced (mean adenoviral Ct-values = 24.6, median adenoviral Ct-values = 25.6) and revealed a predominance of HAdV-C species and two specimens identified as HAdV-B3 species. The severity of infection in these identified species consists of saturation of oxygen less than 94%, hospitalization for more than or equal to 7 days, bacterial
| Data specific to the neonatology population | Total, no. (%) | HAdV− | HAdV+ | P-value, OR (95% CI) |
|-------------------------------------------|----------------|-------|-------|---------------------|
| **Demography and medical history**        |                |       |       |                     |
| Age groups, d                             |                |       |       |                     |
| ≤ 10                                      | 36 (17.0)      | 29 (80.5) | 7 (19.5) | .04 1 0.36 (0.13-0.97) |
| 10-45                                     | 175 (83.0)     | 161 (92.0) | 14 (8.0) |                     |
| **Feeding**                               |                |       |       |                     |
| Breast                                    | 39 (32.8)      | 36 (92.3) | 3 (7.7)  | .53                 |
| Artificial                                | 33 (27.7)      | 30 (90.9) | 3 (9.1)  |                     |
| Mixed                                     | 47 (39.5)      | 40 (85.1) | 7 (14.9) |                     |
| **Prematurity**                           |                |       |       |                     |
| No (37-42)                                | 62 (55.9)      | 55 (88.7) | 7 (11.3) | .87                 |
| Yes (≤37)                                 | 49 (44.1)      | 43 (87.8) | 6 (12.2) |                     |
| **Side symptoms/other biological tests**  |                |       |       |                     |
| Body T° (°C)                              |                |       |       |                     |
| ≤36                                       | 5 (4.3)        | 5 (100.0) | 0 | .89 4 (1.1-19.3) |
| 36-37.5                                   | 64 (54.7)      | 55 (86.0) | 9 (14.0) |                     |
| 37.5-38                                   | 24 (20.5)      | 22 (91.7) | 2 (8.3)  |                     |
| >39                                       | 23 (19.7)      | 21 (91.3) | 2 (8.7)  |                     |
| **Digestive signs (no*, yes)**           |                |       |       |                     |
| ≤6                                        | 27 (22.7)      | 21 (77.3) | 6 (22.2) | .02 1 |
| >6                                        | 289 (23.9)    | 224 (77.0) | 65 (23.0) |                     |
| CRP (mg/L)                                |                |       |       |                     |
| ≤6                                        | 87 (73.7)      | 76 (87.4) | 11 (12.6) | .94 4 (1.1-19.3) |
| 6-20                                      | 8 (6.8)        | 7 (87.5)  | 1 (12.5) |                     |
| 21-50                                     | 16 (13.6)      | 15 (93.75)| 1 (6.25) |                     |
| >50                                       | 7 (5.9)        | 7 (100.0) | 0 |                     |
| **Predictive severity symptoms**          |                |       |       |                     |
| Duration of hospitalization, d            |                |       |       |                     |
| ≤ 1.7                                     | 28 (24.1)      | 25 (89.3) | 3 (10.7) | >.99 |
| >1.7                                      | 33 (28.4)      | 29 (87.9) | 4 (12.1) |                     |
| >15                                       | 55 (47.4)      | 49 (80.1) | 6 (19.9) |                     |
| Ventilation (no*, yes)                    |                |       |       |                     |
| ≤3                                        | 4 (28.6)       | 4 (100.0) | 0 | >.99 |
| >3                                        | 10 (71.4)      | 9 (90.0)  | 1 (10.0) |                     |
| Duration of ventilation, d               |                |       |       |                     |
| ≤3                                        | 104 (87.4)     | 92 (88.5) | 12 (11.5) | >.99 |
| >3                                        | 12 (10.1)      | 11 (91.7) | 1 (8.3)  | >.99 |

**Data specific to the pediatric population**

| Total, no. (%) | 372 (63.8) | 279 (75.0) | 93 (25.0) | ... |
| Demography and medical history | Data specific to the neonatology population | Total | HAdV− | HAdV+ | P-value, OR (95% CI) |
|-------------------------------|---------------------------------------------|-------|-------|-------|---------------------|
| **Age groups** | **45 d−3 mo** | 159 (42.7) | 131 (82.4) | 28 (17.6) | .01 1 |
| | **4−6 mo** | 67 (18.0) | 45 (67.2) | 22 (32.8) | 0.37 (0.19−0.73) |
| | **7−12 mo** | 88 (23.7) | 66 (75.0) | 22 (25.0) | 0.86 (0.41−1.8) |
| | **13−60 mo** | 58 (15.6) | 37 (63.8) | 21 (36.2) | 0.58 (0.28−1.2) |
| Asthma (no*, yes) | | 35 (9.4) | 26 (74.3) | 9 (25.7) | >0.99 |
| Feeding | **Breast** | 52 (29.9) | 42 (80.8) | 10 (19.2) | .23 |
| | **Artificial** | 21 (12.1) | 17 (81.0) | 4 (19.0) | |
| | **Mixed** | 101 (58.0) | 70 (69.3) | 31 (30.7) | |
| Prematurity (no*, yes) | | 72 (19.4) | 53 (73.6) | 19 (26.4) | .76 |
| Side symptoms/other biological tests | Anemia (no*, yes) | 192 (54.2) | 143 (74.5) | 49 (25.5) | .55 |
| | Gastroenteritis (no*, yes) | 6 (1.6) | 1 (16.7) | 5 (83.3) | <.01 1 |
| | CRP (mg/L) | **<20** | 229 (65.6) | 176 (76.9) | 53 (23.1) | .46 |
| | | **≥20** | 120 (34.4) | 88 (73.3) | 32 (26.7) | |
| Associated ARIs | Rhinitis (no*, yes) | 79 (21.2) | 59 (74.7) | 20 (25.3) | .96 |
| | Laryngitis (no*, yes) | 18 (48) | 12 (66.7) | 6 (33.3) | .40 |
| | Pharyngitis (no*, yes) | 10 (2.7) | 7 (70.0) | 3 (30.0) | .71 |
| Predictive severity symptoms | Saturation of O₂ < 94% (no*, yes) | 71 (19.3) | 47 (66.2) | 24 (33.8) | .05 1 |
| | Duration of hospitalization, (days) | 0−3 | 56 (15.1) | 44 (78.6) | 12 (21.4) | .58 |
| | | 4−7 | 148 (39.8) | 107 (72.3) | 41 (27.7) | |
| | | >7 | 168 (45.2) | 128 (76.2) | 40 (23.8) | |
| | Admission to ICU (no*, yes) | 47 (12.6) | 37 (78.7) | 10 (21.3) | .52 |
| | Oxygen support (no*, yes) | 109 (31.4) | 84 (77.1) | 25 (22.9) | .43 |
| | Duration of oxygen support, (days) | **<5** | 58 (54.2) | 50 (86.2) | 8 (13.8) | .02 1 |
| | | ≥5 | 49 (45.8) | 33 (67.3) | 16 (32.7) | |
| | Death (no*, yes) | 23 (6.18) | 17 (73.9) | 6 (26.1) | >0.99 |

---

**Note:** HAdV positive and negative detection rates were established as a fraction of the total number of cases defined by each group. Saturation of O₂ defined in the pediatric group, and confirmed when it is inferior to 94%.

**Abbreviations:** ARIs, acute respiratory infections; Body T°, body temperature; CRP, C-reactive protein; ICU, Intensive Care Unit; HAdV, human Adenovirus; NRDS, neonatal respiratory distress syndrome.

*P-value was calculated using the Pearson's χ² test or the Fisher's exact test on SPSS, where appropriate. A value of P ≤ .05 was considered as significant and is bolded in the Table.

**The odds-ratio (OR) and 95% confidence interval [95% CI] were calculated using the parameter risk in crosstabs for variable with two categories or the binary regression model when the test exceeded two tails. OR and 95% CI with a value of P ≤ .05 (statistical significance) are bolded in the Table.

*The diagnosis of prematurity in neonates was estimated according to the amenorrhea week (confirmed if ≤37 amenorrhea week).

*Defines the reference group used in the statistical calculations.
superinfection, two cases admitted in the ICU and infected by
HAdV-C2, and a single fatality identified as HAdV-C5 mono-infection.
The two control specimens (Innsbruck) were identified as HAdV-
F41 (Supplemental Digital Content 1). Six from these sequences were
deposited on GenBank under the accession numbers MK932851 to
MK932856 and included in the phylogenetic tree. All sequences
were variable suggesting the circulation of different HAdV strains,
which shared more similarities to strains circulating in Europe or Asia
than those from Africa (Figure 1).

4 | DISCUSSION

Earlier studies in Tunisia have reported HAdV infection rates of 19.5%17
and 25.8%14 in children with community-acquired LARIs, and conform
to this study which detected HAdV in 19.6% of tested samples. Thus,
HAdV-detection in the respiratory tract is important and should be
considered in clinical settings. Indeed, throughout the world, HAdV has
been shown to cause between 5% and 15% of UARIs and about 5% of
LARIs in children.6,29 This study has discovered that HAdV seems to
increase the risk of low oxygen saturation and the duration of oxygen
support in the pediatric environment which is in line with other reports
showing that HAdV is associated with severe clinical manifestations.30,31 In Africa, HAdV was associated with influenza-like illnesses in
several countries like Morocco, Egypt, Cameroon, and Senegal.13,32,34
However, the severity of respiratory infections was variable. In Cam-
eroon, HAdV was not found to be associated with severity.33 Conversely, in Senegal, HAdV infection was statistically correlated with
myalgia, cough, diarrhea, headache, rhinitis, and pharyngitis.34 In the
present study, a statistically significant association was found between
HAdV infection and the manifestation of gastroenteritis and digestive
symptoms. About two-third of infected cases needed oxygen support for
more than 5 days; although, less than the half the cases negative for
HAdV required long duration of oxygen support. This finding was sup-
ported by other reports indicating that children with severe HAdV in-
fecion including acute respiratory distress syndrome and respiratory
failure need prolonged mechanical support in the form of either me-
chanical ventilation or extracorporeal life support and that early ex-
tracorporeal membrane oxygenation intervention for children should be
considered.35 Another study reported that severe HAdV type 55 in-
fecion in adults causes rapid progression of respiratory failure with a
high failure rate for noninvasive positive pressure ventilation and in-
vasive mechanical ventilation. This failure rate may result to a large area
of consolidation that induces a severe shunt in the lung, which will lead
to a lack of response to positive pressure ventilation. For patients with
severe acute respiratory distress syndrome, extracorporeal membrane
oxygenation should be considered a better choice for oxygenation.36

Studies indicate that HAdV coinfections with other viral/bac-
terial agents may cause more severe disease. In this study, 93.9% of
all HAdV specimens were coinfected with at least one other patho-
gen. The association between adenoviral coinfections with other viral
agents and clinical data or severity of ARIs determined by this study,
showed no association, suggesting that viral superinfection had no
additional pathogenic role, supporting other findings.77 On the con-
trary to viral coinfections detected in this study, more severe infec-
tions were described in combination with HAdV-S. pneumoniae, which
seems to increase the risk of death. In corroboration to our finding, it
was demonstrated that HAdV, particularly types 1, 2, 3, and 5 en-
hance pneumococcal adherence to the human respiratory epithelial
cell culture due to an upregulation of receptors for S. pneumoniae.38

| TABLE 3 | Statistical associations between human Adenovirus coinfections with other respiratory infectious agents and predictive severity factors |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Patients data                    | HAdV- HRSV A/B positive | HAdV- HRSV A/B positive | HAdV- HRSV A/B positive | HAdV- HRSV A/B positive | HAdV- HRSV A/B positive | HAdV- HRSV A/B positive | HAdV- HRSV A/B positive | HAdV- HRSV A/B positive | HAdV- HRSV A/B positive | HAdV- HRSV A/B positive |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Total (114)                      | 56              | 58              | ...             | 80              | 34              | ...             | 75              | 39              | ...             | 89              | 25              | ...             |
| Admission Neo                    | 16 (28.6)       | 5 (8.6)         | <.01            | 14 (17.5)       | 7 (20.6)        | .69             | 16 (21.3)       | 5 (12.8)        | .26             | 18 (20.2)       | 3 (12.0)        | .56             |
| Prematurity                      | 6 (15.0)        | 13 (24.5)       | .26             | 14 (21.2)       | 5 (18.5)        | .77             | 15 (25.4)       | 4 (11.8)        | .11             | 14 (19.7)       | 5 (22.7)        | .76             |
| Ventilation                      | 4 (7.1)         | 6 (10.3)        | .74             | 5 (6.3)         | 5 (14.7)        | .16             | 6 (8.0)         | 4 (10.3)        | .73             | 7 (7.9)         | 3 (12.0)        | .45             |
| Death**                         | 3 (5.4)         | 6 (10.3)        | .49             | 6 (7.5)         | 3 (8.8)         | >.99            | 3 (4.0)         | 6 (15.4)        | .06             | 6 (6.7)         | 3 (12.0)        | .40             |

Note: The percentages were calculated as a fraction of the total number of HAdV coinfections defined by each category (negative and positive coinfections). Data increasing with positive HAdV coinfections were represented in the Table in bold. Abbreviations: HAdV, human Adenovirus; HCoVs, human Coronavirus group including HCoV-229E, HCoV-HKU1, HCoV-OC43, and HCoV-NL63; HRV, human Rhinovirus; HRSV A/B, human Respiratory Syncytial virus A/B; ICU, Intensive Care Unit; Neo, neonatology ward; Ped, pediatric ward; S. pneumoniae, Streptococcus pneumoniae.

*P-value was calculated using the χ² test or Fisher’s exact test on SPSS, where appropriate. A value of P ≤ .05 was considered as significant and is bolded in the Table.

**No statistical associations were evaluated for death due to the small number of identified cases (solely seven cases).
TABLE 4  Clinical profile and predictive severity factors of human *Adenovirus* identified types from patients hospitalized for acute respiratory infections between 2013 and 2014

| Patient ID | Age (mo) | Underlying disease | Clinical diagnosis | Severity and complication of ARIs | Coinfections | Ct-value | Typing | Sequencing/AN |
|------------|----------|---------------------|--------------------|-----------------------------------|--------------|----------|--------|---------------|
| 1          | 5        | Asthma              | Bronchiolitis      | Hospitalization for 13 d, saturation of $O_2 < 94\%$ | HRV and *S. pneumoniae* | 23.56     | ...    | HAdV-C type 1/ MK932852 |
| 2          | 57       | Asthma, passive smoking | Bronchiolitis      | Hospitalization for 10 d, saturation of $O_2 < 94\%$ | HBoV         | 26.17     | ...    | HAdV-C type 1/ MK932853 |
| 3          | 23       | ...                 | Bronchiolitis      | Admission to ICU (3 d), dehydration | HRV and HBoV | 14.18     | HAdV-2 | HAdV-C type 2 |
| 4          | 23       | ...                 | Bronchiolitis      | Admission to ICU (2 d), apnea | HRV, HMPV A/B, and HBoV | 27.12     | HAdV-2 | HAdV-C type 2/ MK932854 |
| 5          | 19       | Prematurity         | Bronchiolitis and laryngitis | Bacterial superinfection | *S. pneumoniae* | 26.94     | ...    | HAdV-C type 5/ MK932851 |
| 6          | 1        | ...                 | Bronchiolitis and rhinitis | Hospitalization for 16 d, bacterial superinfection | ... | 23.71     | ...    | HAdV-C type 5/ MK932856 |
| 7          | 6        | ...                 | Bronchiolitis and rhinitis | Bacterial superinfection | HRV         | 25.02     | HAdV-3 | HAdV-B type 3 |
| 8          | 3        | Asthma              | Bronchiolitis      | Hospitalization for 9 d, oxygen support (5 d), dehydration, bacterial superinfection | HRSV A/B, *S. pneumoniae*, and PeV | 24.46     | ...    | HAdV-C type 1 |
| 9          | 4        | Passive smoking     | Bronchiolitis      | ... | HMPV A/B and EV | 27.29     | HAdV-2 | HAdV-C type 2 |
| 10         | 6        | Passive smoking     | Bronchiolitis      | Hospitalization for 10 d, nosocomial infection, death | HRSV A/B and *S. pneumoniae* | 22.81     | ...    | HAdV-C type 5 |
| 11         | 8        | Asthma, passive smoking | Bronchiolitis and rhinitis | bacterial superinfection | HRV | 26.60     | HAdV-3 | HAdV-B type 3 |
| 12         | 7        | Passive smoking     | Bronchiolitis, pharyngitis, and gastroenteritis | Hospitalization for 15 d, nosocomial infection | HCoV-229E | 27.76     | HAdV-2 | HAdV-C type 2 |

Note: The saturation of $O_2$ was defined in the pediatric group and was confirmed when it is inferior to 94%. Abbreviations: AN, Accession Number; CRP, C-reactive protein; EV, Enterovirus genus; F, female; HAdV, human *Adenovirus*; HBoV, human Bocavirus; HCoV-229E, human Coronavirus 229E; HMPV A/B, human Metapneumovirus A/B; PeV, Parechovirus genus; HRV, human Rhinovirus; ICU; Intensive Care Unit; M, male, *S. pneumoniae*, Streptococcus pneumoniae.

*The patient’s age was described in month(s).*

*Clinical diagnosis of patients and infections (laryngitis, rhinitis, pharyngitis, and gastroenteritis) associated with bronchiolitis.*

*All the HAdV identified types presented symptoms of severe ARIs including mostly long duration of hospitalization, bacterial superinfection, admission to ICU, oxygen support, saturation of $O_2 < 94\%$, and death.*

*The adenoviral Ct-values were established from the multiplex qRT-PCR.*

*As primers used for HAdV typing by conventional PCR were not able to characterize all HAdV types, only HAdV types 2 and 3 were identified. Sequencing reactions established other HAdV including types 5 and 1.*

*HAdV infection associated with fatality.*
By this mechanism, HAdV-associated ARIs may favor pneumococcal infections, which lead to severe diseases and deaths in patients under 5 years of age.

The role of HAdV in the pathogenesis of ARIs is still not clear. The high rate of coinfections found in this study and by others initiates the discussion as to whether HAdV contributes to the manifestation of ARIs. Indeed, some authors hypothesize that the multiplex molecular methods can simultaneously identify a wide range of pathogens, which are putative bystander infections/reactivations with no or limited causative role for the pathogenesis.\textsuperscript{8,39} Though the total number of HAdV single infections in our study is too small (solely seven cases) to be statistically analyzed, HAdV infection is likely to be the causative agent for ARIs in these cases, as no other viral pathogen was detected. To provide a conclusive support for the hypothesis that HAdV is definitely implicated in ARIs, a larger patient cohort needs to be analyzed, and bacteria should be included.

Besides correlations with the severity of respiratory diseases, other approaches have been proposed for a better understanding of the role of HAdV in ARIs. The determination of viral loads and specific Ct-values has been suggested to be considered.\textsuperscript{40} According to Esposito et al.,\textsuperscript{41} low Ct-values and thus high viral loads had a trend towards more complex disease in HAdV-C respiratory infection. Moreover, a study done in Kuwait found that 75\% of patients with HAdV severe respiratory infection had Ct-values less than 30 cycles.\textsuperscript{42} In this study, no correlation could be established between the severity of ARI and Ct-values except an increasing risk of anemia. This lack of association could be related to the insufficient number of specimens with high adenoviral loads. Some authors suggested performing a cell culture for specimens with high Ct-values to increase the number of HAdV particles,\textsuperscript{43} however, the significance of low adenoviral loads in respiratory samples remains unclear and needs further and larger studies.

Within HAdV positive samples, only 12 were successfully typed and sequenced revealing one of the study limitations. Similarly, studies from Cameroon\textsuperscript{29} and China\textsuperscript{44} that sequenced specimens based on a partial hexon gene showed successful sequencing of under 11\% of the
samples. The difference in the sensitivity of qPCR used for HAdV-detection could justify these results. Indeed, Kenmoe et al.\textsuperscript{22} found a significantly low viral load of non-typed samples with standard PCR compared to successfully typed samples (mean Ct-values of 28.9 vs 15.4, respectively). In this study, the mean Ct-values for non-typed samples were 34.4 against 24.6 for successfully typed samples.

Most of the HAdV-positive infections detected in this study were HAdV-C followed by HAdV-B. A report from Cameroon found that HAdV-B infections were more common and severe than HAdV-C.\textsuperscript{33} On the contrary, studies conducted in Egypt and Senegal were consistent with our findings showing a predominance of HAdV-C.\textsuperscript{10,34} The most frequently identified types in this study were HAdV-C1, -C2, and -C5. This data is in line with the epidemiology of HAdV worldwide, which found these types in children with ARIs.\textsuperscript{55} The HAdV-C infected patients identified in the present study had severe clinical manifestations with one fatal case infected by HAdV-C5. A study in the United States determining the risk factors for severe HAdV infection found that HAdV-C5 increased the risk of severe disease.\textsuperscript{46} In addition, HAdV-B species including types 3 and 7, and in some cases types 14, 21, and 55, and HAdV-E species with the single known type 4, were also associated with severe clinical forms in the pediatric population requiring hospitalization.\textsuperscript{36,47,48} Sequences identified in the present study were variable suggesting the circulation of different HAdV strains. Unfortunately, comparison with previous HAdV strains identified in ARIs in Tunisia was not possible as no Tunisian HAdV sequences were published. Here, only sequences concerning enteric or environmental HAdV were available.\textsuperscript{19,20,49,50}

Although the multiplex qRT-PCR can detect simultaneously a wide range of respiratory pathogens, low viral loads are probably not indicative of viral pathogenesis. The standard PCR used for typing and sequencing is based on the hexon gene, which allows more specific differentiation of adenoviral subtypes. However, it has the disadvantage of low sensitivity and requires samples with high viral loads. In addition, the fewer number of HAdV genotypes and sequences covered by the present study are considered among the study limitations. This number should be increased by referring to cell culture for samples with low viral loads or/and increasing the sampling size of the study population.

5 | CONCLUSION

This study provides the first molecular and epidemiological description of HAdV-ARIs circulating in Tunisia. Bacterial coinfections, especially with S. pneumoniae, seem to play a role. On the contrary, coinfections of respiratory viruses with HAdV do not seem to increase the severity of ARIs. Further studies with larger sampling are needed to clarify the role of HAdV loads or adenoviral Ct-values and the role of HAdV genotypes in ARIs.

ACKNOWLEDGMENTS

We are thankful to Dr Albert Heim from the Institute of Virology (Medical University of Hannover, Germany) for the HAdV primers design. We are grateful to Dr Wegene Borena from the Institute of Virology, Medical University of Innsbruck, Austria and to Dr Sana Bhiri from the Department of Prevention and Care Safety (Hôpital Universitaire Sahloul, Sousse, Tunisia) for their assistance with statistical analysis. The present study was supported by the Austrian Science Fund (FWF-HOROS Doctoral Program, W-1253 DK HOROS, horos@i-med.ac.at) and the Ministry of Higher Education and Scientific Research in Tunisia (MHESR).

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Ines Brini
http://orcid.org/0000-0002-1733-6884

REFERENCES

1. Brealey JC, Sly PD, Young PR, Chappell KJ. Viral bacterial co-infection of the respiratory tract during early childhood. FEMS Microbiol Lett. 2015;362:10.
2. Lu X, Erdman DD. Molecular typing of human adenoviruses by PCR and sequencing of a partial region of the hexon gene. Arch Virol. 2006;151(8):1587-1602.
3. Kajon AE, Lamson DM St., George K. Emergence and re-emergence of respiratory adenoviruses in the United States. Curr Opin Virol. 2019;34:63-69.
4. Lynch JP, Kajon AE. Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention. Semin Respir Crit Care Med. 2016;37(4):586-602.
5. Scott MK, Chommanard C, Lu X, et al. Human adenovirus associated with severe respiratory infection, Oregon, USA, 2013-2014. Emerg Infect Dis. 2016;22(6):1044-1051.
6. Singh-Naz N, Rodriguez W. Adenoviral infections in children. Adv Pediatr Infect Dis. 1996;11:365-388.
7. Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev. 2014;27(2):441-462.
8. Schijnderup Nilsen H-J, Nordbaa SA, Kroksstad S, Dellner H, Christensen A. Human adenovirus infection in immunocompetent and immunocompromised patients. J Clin Virol. 2019;111:19-23.
9. Rodriguez-Martinez CE, Rodriguez DA, Nino G. Respiratory Syncytial Virus, Adenoviruses, and Mixed Acute Lower Respiratory Infections in Children in a Developing Country. J Med Virol. 2015;87(5):774-781.
10. Demian PN, Horton KC, Kajon A, et al. Molecular identification of adenoviruses associated with respiratory infection in Egypt from 2003 to 2010. BMC Infect Dis. 2014;14:50.
11. O'Meara WP, Mott JA, Laktabai J, et al. Etiology of pediatric fever in western Kenya: a case-control study of falciparum malaria, respiratory viruses, and streptococcal pharyngitis. Am J Trop Med Hyg. 2015;92(5):1030-1037.
12. Kadi Z, Bouguermouh A, Belhocine Z, et al. Acute respiratory infections of viral origin in the children of Algiers, Algeria based on a seroepidemiological study. Rev Roum Virol. 1990;41(3-4):197-207.
13. Jouundi I, Mahraoui C, Benmessoud R, et al. The epidemiology and aetiology of infections in children admitted with clinical severe pneumonia to a university hospital in Rabat, Morocco. J Trop Pediatr. 2014;60(4):270-278.
14. Berrajah LF, Ben Slama KA, Khbou I, et al. Virus and atypical pathogens detected in community-acquired lower respiratory tract
infection in infants and children of Sfax Region, Tunisia. Bull Soc Pathol Exot. 2018;111(2):90-98.

15. Brini I, Guerrero A, Hannachi N, et al. Epidemiology and clinical profile of pathogens responsible for the hospitalization of children in Sousse area, Tunisia. PLoS One. 2017;12(11):e0188325.

16. Brini Khalifa I, Hannachi N, Guerrero A, et al. Demographic and seasonal characteristics of respiratory pathogens in neonates and infants aged 0 to 12 months in the Central-East region of Tunisia. J Med Virol. 2018;91(4):570-581.

17. El Moussi A, Pozo F, Ben Hadj Kacem MA, et al. Virological surveillance of influenza viruses during the 2008-09, 2009-10 and 2010-11 seasons in Tunisia. PLoS One. 2013;8(9):e74064.

18. Haddad-Boubaker S, Joffret M-L, Péro P, et al. Metagenomic analysis identifies human adenovirus 31 in children with acute flaccid paralysis in Tunisia. Arch Virol. 2019;164(3):747-755.

19. Ibrahim C, Hassen A, Pothier P, Mejri S, Hammami S. Molecular detection and genotypic characterization of enteric adenoviruses in a hospital wastewater. Environ Sci Pollut Res Int. 2018;25(11):10977-10987.

20. Sdiri-Loulizi K, Gharbi-Khelifi H, de Rougemont A, et al. Molecular epidemiology of human astrovirus and adenovirus serotypes 40/41 strains related to acute diarrhea in Tunisian children. J Med Virol. 2009;81(11):1895-1902.

21. Fodha I, Chouikha A, Peenze I, et al. Identification of viral agents causing diarrhea among children in the Eastern Center of Tunisia. J Med Virol. 2006;78(9):1198-1203.

22. La STP. bronchiolite aigue: diagnostic et traitement. Recommandations de la Société Tunisienne de Pédiatrie. 2013:1-38.

23. Corless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarski EB. Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of meningitis and septicaemia using real-time PCR. J Clin Microbiol. 2001;39(4):1553-1558.

24. Sarantis H, Johnson G, Brown M, Petric M, Tellier R. Comprehensive Detection and Serotyping of Human Adenoviruses by PCR and Sequencing. J Clin Microbiol. 2004;42(9):3963-3969.

25. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser. 1999;41:95-98.

26. Ronquist F, Huelsenbeck JP. MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics. 2003;19(12):1572-1574.

27. Rambaut A FigTree. 2012; http://tree.bio.ed.ac.uk/software/figtree/, Accessed February 2020.

28. Hogg RVT, Elliott A. Probability and Statistical Inference. 7th ed. Upper Saddle River, NJ: Prentice Hall; 2006.

29. Taylor S, Lopez P, Weckx L, et al. Respiratory viruses and influenza-like illness: epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample. J Infect. 2017;74(1):29-41.

30. Scott MK, Chomnanard C, Lu X, et al. Human Adenovirus associated with severe respiratory infection, Oregon, USA, 2013-2014. Emerg Infect Dis. 2016;22(6):1044-1051.

31. Zampoli M, Mukuddem-Sablaz Y. Adenovirus-associated pneumonia in South African children: presentation, clinical course and outcome. South Afr Med J. 2017;107(2):123-126.

32. Rowlinson E, Duerer G, Mansour A, et al. Incidence and etiology of hospitalized acute respiratory infections in the Egyptian Delta. Influenza Other Respir Viruses. 2017;11(1):23-32.

33. Keenoe S, Vernet M-A, Le Goff J, Penlap VB, Vabret A, Njuom R. Molecular characterization of human adenovirus associated with acute respiratory infections in Cameroon from 2011 to 2014. Virol J. 2018;15(1):153.

34. Niang MN, Diop NS, Fall A, et al. Respiratory viruses in patients with influenza-like illness in Senegal: focus on human respiratory adenoviruses. PLoS One. 2017;12(3):e0174287.

35. Hung K-H, Lin L-H. Adenovirus pneumonia complicated with acute respiratory distress syndrome. Medicine. 2015;94:20.

36. Sun B, He H, Wang Z, et al. Emergent severe acute respiratory distress syndrome caused by adenovirus type 55 in immunocompetent adults in 2013: a prospective observational study. Crit Care. 2014;18(4):456.

37. Malekshahi SS, Shafiei-Jandaghi NZ, Yavarian J, Shadab A, Naseri M, Azad TM. Detection of respiratory co-infections in children less than five years with adenovirus infection. Arch Pediatr Infect Dis. 2017;3(1):e36953.

38. Håkansson A, Kiii A, Wedell G, Sabharwal H, Svanborg C. Adenovirus infection enhances in vitro adherence of Streptococcus pneumoniae. Infect Immun. 1994;62(7):2707-2714.

39. Deng J, Ma Z, Huang W, et al. Respiratory virus multiplex RT-PCR assay sensitivities and influence factors in hospitalized children with lower respiratory tract infections. Virol Sin. 2013;28(2):97-102.

40. Gu L, Qu J, Sun B, Yu X, Li H, Cao B. Sustained viremia and high viral load in respiratory tract secretions are predictors for death in immunocompetent adults with adenovirus pneumonia. PLoS One. 2016;11(8):e0160777.

41. Esposito S, Zampiero A, Bianchini S, et al. Epidemiology and clinical characteristics of respiratory infections due to adenovirus in children living in Milan, Italy, during 2013 and 2014. PLoS One. 2016;11(4):e0152375.

42. Chehadeh W, Al-Adwani A, John SE, et al. Adenovirus types associated with severe respiratory diseases: a retrospective 4-year study in Kuwait. J Med Virol. 2018;90(6):1033-1039.

43. Thouaajam JD, Balakrishnan A, Mun AB. Detection and molecular typing of human Adenoviruses associated with respiratory illnesses in Kerala. Jpn J Infect Dis. 2016;69(6):500-504.

44. Liu C, Xiao Y, Zhang J, et al. Adenovirus infection in children with acute lower respiratory tract infections in Beijing, China, 2007 to 2012. BMC Infect Dis. 2015;15:408.

45. Schmitt H, Wigand R, Heinrich W. Worldwide epidemiology of human adenovirus infections. Am J Epidemiol. 1983;117(4):455-466.

46. Gray GC, McCarthy T, Lebeck MG, et al. Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006. Clin Infect Dis. 2007;45(9):1120-1131.

47. James AG, Lang WR, Liang AY, et al. Adenovirus type 21 bronchopneumonia in infants and young children. J Pediatr. 1979;95(4):530-533.

48. Kajon AE, Murtagh P, Garcia Franco S, Freire MC, Weissenbacher MC, Zorózopulos J. A new genome type of adenovirus 3 associated with severe lower acute respiratory infection in children. J Med Virol. 1990;30(1):73-76.

49. Sdiri-Loulizi K, Hassine M, Aouni Z, et al. Detection and molecular characterization of enteric viruses in environmental samples in Monastir, Tunisia between January 2003 and April 2007. J Appl Microbiol. 2010;109(3):1093-1104.

50. Fedaoui N, Ben Ayed N, Ben Yahia A, et al. Molecular detection and characterization through analysis of the hexon and fiber genes of Adenoviruses causing conjunctivitis in Tunisia, North Africa. J Med Virol. 2017;89(2):304-312.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Brini I, Guerrero A, Ezzine I-K, et al. Human adenoviruses associated with respiratory illness in neonates, infants, and children in the Sousse area of Tunisia. J Med Virol. 2020;92:3081–3092. https://doi.org/10.1002/jmv.26375